Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial tests a special injection to numb liver nerves and reduce pain in patients undergoing painful liver tumor treatments. The injection uses a medication to numb the nerves around the liver, helping to lessen pain during and after the procedures.

Eligibility Criteria

Treatment Details

4Treatment groups

Experimental Treatment

Placebo Group

Group I: Hepatic hilar nerve block in chemoembolization patientsExperimental Treatment2 Interventions

15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.

Group II: Hepatic hilar nerve block in ablation patientsExperimental Treatment2 Interventions

15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.

Group III: Placebo procedure in ablation patientsPlacebo Group2 Interventions

15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.

Group IV: Placebo procedure in chemoembolization patientsPlacebo Group2 Interventions